BLACK WEEKSFlaconcini −15% · kit −10% · resto −5%con il codiceSpedizione gratuita in Germania da 200 €

Questa pagina è stata tradotta automaticamente e può contenere errori. Sei madrelingua? Saremo felici di ricevere il tuo feedback e le tue correzioni.Invia feedback

The Peptide Desk The Peptide Desk
BPC-157 Oral, foto del prodotto
Healing Oral

BPC-157 Oral

Healing Oral

  • Spedito dalla Germania

Ordine

Prezzo unitario - Spedizione gratuita in Germania da 200 € durante le Black Weeks
  • DHL con tracciamento
  • Imballaggio discreto

4.6 su 5 su Trustpilot73 recensioni

In sintesi

BPC-157 Oral in cifre

I dati chiave dalla nostra enciclopedia.

Voce completa dell'enciclopedia
Class
Pentadecapeptidehealing, oral
Use
Oralcapsule, 500mcg
Sizes
500 mcg1 size in the shop

What studies show

The source in the lexicon
  1. Stable gastric pentadecapeptide BPC 157 and wound healing (review) (opens in a new tab)

    Seiwerth, Sikiric et al., Frontiers in Pharmacology, 2021

Non esiste ancora un'analisi di laboratorio per BPC-157 Oral. Vota a favoreFallo testare tu, noi paghiamo la metàTutte le analisi di laboratorio

Conoscenze

Tutto su BPC-157 Oral

FAQ

Domande frequenti

Fonti per ogni risposta: voce dell'enciclopedia

Hai ancora una domanda?

Scrivici, il nostro team ti aiuterà.

Is the capsule different from the tablet?

Not in terms of the compound. Capsule and tablet both contain BPC-157, only the shell differs. There are no comparative data on capsule versus tablet and no human study of either form.

Is BPC-157 absorbed by mouth at all?

According to a review by the developer group, BPC-157 is stable in human gastric juice. In rat studies it worked via the drinking water much like when injected. There are no blood measurements after oral dosing. After dosing into muscle 14 to 19 percent reached the blood in rats and 45 to 51 percent in dogs, the half-life was under 30 minutes.

What do the animal studies show for the gut?

In rats with a fistula between colon and skin the colon and skin defects healed faster when BPC-157 was injected or added to the drinking water. In short bowel syndrome the animals given BPC-157 by mouth or by injection started gaining weight again right away. There are also findings on alcohol and painkiller damage to the stomach and oesophagus.

Are there studies in humans?

Very few. A systematic review up to June 2026 found three studies with 30 people in total: knee injections, dosing into the bladder and a small safety study into a vein. All without a control group, none with a capsule or tablet. A registered phase 1 tablet trial from 2015 has not published results to this day.

Which trials are running right now?

As of 26 October 2026 no trial with BPC-157 is recruiting. A phase 1 trial with 30 planned participants after shoulder surgery has been announced, where BPC-157 is injected under the skin, with the start planned for January 2027. No capsule trial is registered.

Which side effects are known?

No treatment-related side effects occurred in the three small human studies, but the certainty is very low. One review found no clinical safety data and names risks from unregulated manufacturing and contamination. There are no data of its own on the capsule.

Correlati

Prodotti correlati